Fecal Microbiota Transplantation in Recurrent Infection: A Retrospective Single-center Chart Review

Overview

Journal JGH Open

Specialty Gastroenterology

Date 2019 Mar 6

PMID 30834334

Citations 12

Authors

Pamela Kim

Akash Gadani

Heitham Abdul-Baki

Ricardo Mitre

Marcia Mitre

Affiliations

Soon will be listed here.

Abstract

Background And Aim: Fecal microbiota transplantation (FMT) has been proposed as a treatment option for patients with recurrent (C. difficile) infection but remains a novel option. We examined if FMT is an effective means of treating recurrent infection.

Methods: A retrospective review of 35 patients who underwent FMT was completed. Demographics and other variables, including the use of proton pump inhibitor therapy and history of inflammatory bowel disease, were collected.

Results: Twenty-five patients (71.4%) belonged to a high-risk population (working in a hospital setting, rehabilitation center, or nursing facility) and a total of 74.3% of patients ( = 26 patients) had no history of proton pump inhibitor use. Twenty-five patients (71.4%) had used metronidazole prior to transplantation, 35 patients (100%) had used vancomycin, and 7 patients (20%) had used fidaxomicin for prior infection. Four patients (11.4%) had used all three antibiotics during prior treatment. Of the eight patients who had a history of inflammatory bowel disease, six (75%) experienced resolution of symptoms after transplantation. A total of 30 patients (85.7%) had resolution of their symptoms 6-8 weeks' posttransplant, while 5 patients (14.3%) continued to have symptoms.

Conclusions: Our retrospective chart review supports that patients benefit from FMT in the setting of recurrent infection.

Citing Articles

Current and Ongoing Developments in Targeting Infection and Recurrence.

Cun W, Keller P, Pyne S Microorganisms. 2024; 12(6).

PMID: 38930588 PMC: 11205563. DOI: 10.3390/microorganisms12061206.

Effects of dietary energy levels on microorganisms and short-chain fatty acids of rumen and tight junction proteins in Honghe Yellow cattle.

Yu Y, Zi Y, Fu R, Fu B, Li C, Lv Y Front Microbiol. 2024; 15:1335818.

PMID: 38628860 PMC: 11018944. DOI: 10.3389/fmicb.2024.1335818.

The Impact of Microbiota on the Gut-Brain Axis: Examining the Complex Interplay and Implications.

Chaudhry T, Senapati S, Gadam S, Mannam H, Voruganti H, Abbasi Z J Clin Med. 2023; 12(16).

PMID: 37629273 PMC: 10455396. DOI: 10.3390/jcm12165231.

Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection.

Aby E, Vaughn B, Enns E, Rajasingham R Clin Infect Dis. 2022; 75(9):1602-1609.

PMID: 35275989 PMC: 9617579. DOI: 10.1093/cid/ciac207.

The Microbiome in Childhood Acute Lymphoblastic Leukemia.

Oldenburg M, Ruchel N, Janssen S, Borkhardt A, Gossling K Cancers (Basel). 2021; 13(19).

PMID: 34638430 PMC: 8507905. DOI: 10.3390/cancers13194947.

References

McFarland L, Elmer G, Surawicz C . Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97(7):1769-75. DOI: 10.1111/j.1572-0241.2002.05839.x. View

Redelings M, Sorvillo F, Mascola L . Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis. 2008; 13(9):1417-9. PMC: 2857309. DOI: 10.3201/eid1309.061116. View

Cohen S, Gerding D, Johnson S, Kelly C, Loo V, McDonald L . Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31(5):431-55. DOI: 10.1086/651706. View

Landy J, Al-Hassi H, McLaughlin S, Walker A, Ciclitira P, Nicholls R . Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther. 2011; 34(4):409-15. DOI: 10.1111/j.1365-2036.2011.04737.x. View

Khanna S, Pardi D . Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012; 87(11):1106-17. PMC: 3541870. DOI: 10.1016/j.mayocp.2012.07.016. View

Rohlke F, Stollman N . Fecal microbiota transplantation in relapsing Clostridium difficile infection. Therap Adv Gastroenterol. 2012; 5(6):403-20. PMC: 3491681. DOI: 10.1177/1756283X12453637. View

van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal E, de Vos W . Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368(5):407-15. DOI: 10.1056/NEJMoa1205037. View

Chitnis A, Holzbauer S, Belflower R, Winston L, Bamberg W, Lyons C . Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med. 2013; 173(14):1359-67. DOI: 10.1001/jamainternmed.2013.7056. View

Karadsheh Z, Sule S . Fecal transplantation for the treatment of recurrent clostridium difficile infection. N Am J Med Sci. 2013; 5(6):339-43. PMC: 3731863. DOI: 10.4103/1947-2714.114163. View

10.

Kelly C, Ihunnah C, Fischer M, Khoruts A, Surawicz C, Afzali A . Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014; 109(7):1065-71. PMC: 5537742. DOI: 10.1038/ajg.2014.133. View

11.

Lessa F, Mu Y, Bamberg W, Beldavs Z, Dumyati G, Dunn J . Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015; 372(9):825-34. PMC: 10966662. DOI: 10.1056/NEJMoa1408913. View

12.

McDonald E, Milligan J, Frenette C, Lee T . Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection. JAMA Intern Med. 2015; 175(5):784-91. DOI: 10.1001/jamainternmed.2015.42. View

13.

Agrawal M, Aroniadis O, Brandt L, Kelly C, Freeman S, Surawicz C . The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals. J Clin Gastroenterol. 2015; 50(5):403-7. DOI: 10.1097/MCG.0000000000000410. View

14.

Mandalia A, Ward A, Tauxe W, Kraft C, Dhere T . Fecal transplant is as effective and safe in immunocompromised as non-immunocompromised patients for Clostridium difficile. Int J Colorectal Dis. 2015; 31(5):1059-1060. PMC: 4808452. DOI: 10.1007/s00384-015-2396-2. View

15.

Zhang S, Palazuelos-Munoz S, Balsells E, Nair H, Chit A, Kyaw M . Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study. BMC Infect Dis. 2016; 16(1):447. PMC: 5000548. DOI: 10.1186/s12879-016-1786-6. View

16.

Konig J, Siebenhaar A, Hogenauer C, Arkkila P, Nieuwdorp M, Noren T . Consensus report: faecal microbiota transfer - clinical applications and procedures. Aliment Pharmacol Ther. 2016; 45(2):222-239. PMC: 6680358. DOI: 10.1111/apt.13868. View

17.

Bafeta A, Yavchitz A, Riveros C, Batista R, Ravaud P . Methods and Reporting Studies Assessing Fecal Microbiota Transplantation: A Systematic Review. Ann Intern Med. 2017; 167(1):34-39. DOI: 10.7326/M16-2810. View

18.

Quraishi M, Widlak M, Bhala N, Moore D, Price M, Sharma N . Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017; 46(5):479-493. DOI: 10.1111/apt.14201. View

19.

Jalanka J, Hillamaa A, Satokari R, Mattila E, Anttila V, Arkkila P . The long-term effects of faecal microbiota transplantation for gastrointestinal symptoms and general health in patients with recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2017; 47(3):371-379. DOI: 10.1111/apt.14443. View

20.

McDonald L, Gerding D, Johnson S, Bakken J, Carroll K, Coffin S . Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66(7):987-994. DOI: 10.1093/cid/ciy149. View